Granted Janssen was a much much bigger deal but Genetech have marginally increased the cashflow to company at a less advanced stage.
Janssen went Licensing Agreement - Extension - Expansion - Walk for $2.3m Genentech have gone Research Agreement - Licensing Agreement - Extension for $2.5m.
Also worth noting i guess as a whole Roche / Genrntech have contributed more through earlier and expired agreements in a different area of focus. Roche was alwsys pretty tight on the numbers but i think it was about $500k over 3 years targetting the blood brain barrier & delivery. So i guess you could say $3m in total ?
Ann: Operational Update, page-46
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $909.8M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 18.5¢ | $331.8K | 1.731M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 711601 | 7 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |